"These data suggest we may be looking at a significant advance in treatment options for coronary disease that allows precise stent-based delivery of drug and is capable of reducing long-term safety complications," said Alexandre Abizaid, MD, the chief of coronary interventions at the Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil and visiting professor of medicine at Columbia University, New York, USA. "Since stent thrombosis and the drugs required to protect against it are such significant clinical issues, it is particularly pleasing to see the excellent safety outcomes associated with NEVO?„? maintained over 12 months. These results also suggest the need for further study of whether abbreviating or interrupting antiplatelet therapy with this treatment would result in fewer adverse events than would currently be expected in drug-eluting stent patients."

"The additional positive 12-month results from the NEVO?„? RES-I trial are extremely encouraging as they suggest that NEVO?„? could offer improved patient outcomes in the treatment of coronary artery disease," said Campbell Rogers, M.D., Chief Scientific Officer and Global Head, Research and Development, Cordis Corporation. "NEVO?„? is a critical component of our commitment to providing innovative new products, which are transforming expectations for patients and practitioners in the field of interventional cardiology."

SOURCE Cordis Corporation